Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

Scope

The scope of the report includes -
- Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation.
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
- Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market.
- Competitive landscape analysis with competitive profiling of leading companies.
- Analysis of partnership deals from 2006 to 2010
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics.
- Develop market-entry and market expansion strategies by identifying the key development area
- Understand the factors shaping the Nanotechnology in Drug Delivery
- For understanding the technological trends in the market.
- Identify the key players best positioned to take the advantage of the opportunities in the global market.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Table Of Contents

Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 6
2 Nanotechnology in Drug Delivery - Introduction 7
2.1 Introduction 7
2.2 GBI Research Report Guidance 8
3 Application of Nanotechnology in Drug Delivery 9
3.1 Current Applications of Nano-enabled Drug Delivery 9
3.1.1 Nano-engineered drugs 9
3.1.2 Nano-carriers 10
3.2 Future Applications of Nano-enabled Drug Delivery 11
3.2.1 Gene and Vaccine Delivery 11
3.2.2 Controlled-Release Devices 12
3.2.3 Increased Biocompatibility 12
3.2.4 Improved Drug Bioavailability and Solubility 12
3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT) 12
3.2.6 Tissue Specific Delivery 12
4 Nanotechnology in Drug Delivery - Case Studies 13
4.1 Abraxis Bioscience, Inc. - Paclitaxel-Albumin Nanoparticles (Abraxane) 13
4.2 Nanospectra Biosciences- AuroShell Particles 13
4.3 Calando Pharmaceuticals, Inc. - RONDEL Technology 13
4.4 Starpharma Holdings, Ltd. - Dendrimer-Based VivaGel 14
4.5 Mersana Therapeutics: Fleximer - Camptothecin Conjugate 14
4.6 Elan Corporation - NanoCrystal Technology 14
5 Nanotechnology in Drug Delivery - Market Characterization 16
5.1 Introduction 16
5.2 Nano-enabled Drug Delivery Market Drivers 16
5.2.1 Clinical Benefits of Nano-enabled Drug delivery 16
5.2.2 Value Addition to Existing Pharmaceutical Products through Reformulation 16
5.2.3 Strong Pipeline Portfolio 16
5.3 Nano-Enabled Drug Delivery Market Barriers 17
5.3.1 Poor RandD Facilities and Time Gap between Research and Commercialization 17
5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products 17
5.3.3 Regulatory Hindrance 17
5.4 Opportunity and Unmet Need - Drug Delivery 18
5.4.1 Opportunities 18
5.4.2 Unmet Need 18
5.5 Selected Nano-Enabled Therapeutics Approved by the FDA 20
5.5.1 Doxil (Caelyx) 20
5.5.2 Abraxane 21
5.5.3 AmBisome 22
5.5.4 Diprivan 23
5.5.5 Triglide 24
5.5.6 Myocet 25
5.5.7 DepoCyt 26
5.5.8 DaunoXome 27
5.5.9 Estrasorb 27
5.5.10 Macugen 28
5.5.11 Abelcet 29
5.5.12 Adagen 30
5.5.13 Pegasys 30
5.5.14 Somavert 32
5.5.15 Neulasta 33
5.5.16 Copaxone 34
5.5.17 Amphotec 35
5.5.18 PegIntron 35
5.5.19 Oncaspar 37
5.5.20 Epaxal 38
5.5.21 Elestrin 38
6 Nanotechnology in Drug Delivery - Trend Analysis 40
6.1 Increasing Government Funding for Nanotechnology RandD 40
6.2 Increasing Seed and Early-Stage Venture Capital 40
6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO 40
6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods 41
7 Nanotechnology in Drug Delivery - Regulatory Landscape 42
7.1 Introduction 42
7.2 Europe 44
7.2.1 REACH Regulation 44
7.2.2 European Medicines Agency 46
7.3 The US 46
7.3.1 Environment Protection Agency 46
7.3.2 Food and Drug Administration 47
7.3.3 National Institute of Occupational Safety and Health 47
7.4 Japan 48
8 Nanotechnology in Drug Delivery - Pipeline Analysis 49
8.1 Overview 49
8.1.1 Pipeline Analysis by Phase 50
9 Nanotechnology in Drug Delivery - Strategic Consolidations 55
9.1 Overview 55
9.2 Mergers and Acquisitions 55
9.2.1 Mergers and Acquisitions by Geography 55
9.2.2 Mergers and Acquisitions by Deal value 56
9.2.3 Mergers and Acquisition Analysis by Deal Type 57
9.3 Summary of Major MandA Deals 58
9.3.1 AstraZeneca Acquires MedImmune 58
9.3.2 Pfizer Completes Acquisition of Wyeth 58
9.3.3 Celgene Announces To Acquire Abraxis BioScience 58
9.3.4 Amgen Acquires Abgenix 59
9.3.5 Teva Pharmaceutical Acquires Ivax 59
9.4 Licensing Agreement 60
9.4.1 Deals by Year of Consolidations 60
9.4.2 Deals by Geography 61
9.4.3 Deals by Deal value 62
9.5 Summary of Major MandA Deals 62
9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept 62
9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals 63
9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme 63
9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca 63
9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences 64
10 Nanotechnology in Drug Delivery - Future Players 65
10.1 Overview 65
10.2 Abraxis Bioscience (Abraxis) 66
10.2.1 Overview 66
10.2.2 Business Description 66
10.2.3 Product Portfolio 67
10.3 AlphaRx Corporation 68
10.3.1 Overview 68
10.3.2 Business Description 68
10.3.3 Product Portfolio 69
10.4 Camurus AB 69
10.4.1 Overview 69
10.4.2 Product Portfolio 70
10.5 Eurand 70
10.5.1 Overview 70
10.5.2 Business Description 70
10.5.3 Product Portfolio 71
10.6 NanoBio Corporation 71
10.6.1 Overview 71
10.6.2 Product Portfolio 72
10.7 NanoCarrier 72
10.7.1 Overview 72
10.7.2 Product Portfolio 73
11 Nanaotechnology in Drug Delivery - Appendix 74
11.1 Market Definitions 74
11.2 Abbreviations 74
11.3 Research Methodology 75
11.3.1 Coverage 76
11.3.2 Secondary Research 76
11.3.3 Primary Research 76
11.3.4 Expert Panel Validation 77
11.4 Contact Us 77
11.5 Disclaimer 77
11.6 Sources 77

List of Tables

1.1 List of Tables
Table 1: Elan Pharmaceutical, Drugs Based on NanoCrystal Technology, 2010 15
Table 2: Nanotechnology in Drug Delivery, Global, Regulatory Filing Clinical Pipeline, 2010 50
Table 3: Nanotechnology in Drug Delivery, Global, Phase III Clinical Pipeline, 2010 51
Table 4: Nanotechnology in Drug Delivery, Global, Phase II Clinical Pipeline, 2010 51
Table 5: Nanotechnology in Drug Delivery, Global, Phase I Clinical Pipeline, 2010 52
Table 6: Nanotechnology in Drug Delivery, Global, Preclinical Pipeline, 2010 53
Table 7: Nanotechnology in Drug Delivery, Global, Discovery Pipeline, 2010 54
Table 8: Abraxis BioScience, Inc., Nano-Enabled Drug Delivery Pipeline Products, 2010 67
Table 9: AlphaRx Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 69
Table 10: Camurus AB, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 70
Table 11: Eurand, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 71
Table 12: NanoBio Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 72
Table 13: NanoCarrier, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 73

List of Figures

1.2 List of Figures
Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled Drugs, 2010 7
Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the Pharmaceutical Industry, 2010 9
Figure 3: Nanotechnology in Drug Delivery, Future Application of Nanotechnology in Drug Pharmaceutical Industry, 2010 11
Figure 4: Nanotechnology in Drug Delivery, Global, Driver and Restraints, 2010 17
Figure 5: Nanotechnology in Drug Delivery, Opportunity and Unmet Needs, 2010 19
Figure 6: Nanotechnology in Drug Delivery, Trend Analysis, 2010 40
Figure 7: Nanotechnology in Drug Delivery, Challenges Facing Regulators Regarding Nanotechnology 43
Figure 8: Nanotechnology in Drug Delivery, Global, Pipeline by Therapy Area (%), 2010 49
Figure 9: Nanotechnology in Drug Delivery, Global, Pipeline by Phase (%), 2010 50
Figure 10: Nanotechnology in Drug Delivery, Global, MandA Deals by Geography (%), (2006-2010) 55
Figure 11: Nanotechnology in Drug Delivery, Global, MandA Deals by Deals Value (%), 2006-2010 56
Figure 12: Nanotechnology in Drug Delivery, Global, MandA Deals by Deals Type (%), 2006-2010 57
Figure 13: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Years of Consolidation (%), 2006-2010 60
Figure 14: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Geography (%), 2006-2010 61
Figure 15: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Deals Value (%), 2006-2010 62
Figure 16: Nanotechnology in Drug Delivery, Global, Clinical Pipeline by Company, 2010 65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Receive a detailed analysis of the present and future global market for pulmonary drug delivery technologies. - Receive information on pulmonary drug delivery technologies currently ...

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

nebulizer is a medical device used for the treatment of respiratory disorders (asthma, COPD and cystic fibrosis) that converts liquid medication into mist or aerosol. Thus, the medicine can easily reach ...

Cytotoxic Drug Delivery

May 2014 $ 2 850

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.